Dihexa

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) was developed by researchers at Washington State University as part of investigations into the cognitive-enhancing properties of the angiotensin IV system.

The angiotensin IV receptor (AT4R), also known as IRAP (insulin-regulated aminopeptidase), has been identified as a key regulator of memory acquisition and recall. Dihexa is a stable, orally bioavailable analog that crosses the blood-brain barrier and activates hepatocyte growth factor (HGF) / c-Met signaling.

In preclinical cognitive testing, Dihexa reversed scopolamine-induced cognitive deficits at picomolar concentrations - demonstrating approximately 10 million times the synaptogenic potency of BDNF. It promotes dendritic spine formation and strengthens existing synaptic connections.

This extraordinary potency means effective doses are extremely small, and the compound has demonstrated oral bioavailability, making it one of the most promising cognitive enhancement peptides in research.